Novel targeting compound and use thereof, and nucleic acid conjugate and use thereof
Through the design of novel targeted compounds and nucleic acid conjugates, the problem of low targeted delivery efficiency and high toxicity of RNAi agents in the body is solved, and the efficient gene expression inhibition of liver cells is achieved, especially suitable for the treatment of viruses such as HBV. .
Patent Information
- Application Number
- PCT/CN2024/091851
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art is difficult to effectively deliver RNAi agents to the liver, especially in the extracellular environment in the body (especially serum protein), and there are problems of low delivery efficiency and high toxicity.
A novel targeting compound and nucleic acid conjugate was developed to conjugate to oligonucleotides using specific conjugate groups to form nucleic acid drugs with high delivery efficiency and low toxicity, and to form nucleic acid conjugate by conjugation with siRNA. The compound realizes the regulation of gene expression in hepatocytes. The specific structure includes specific loops A, Z, Y, L, R, etc., and is used to prepare siRNA reagents with high in vivo delivery efficiency and stability.
It has achieved high gene expression inhibitory activity and low toxicity on hepatocytes, improved the in vivo delivery efficiency and stability of RNAi agents, and especially showed high effects in gene expression inhibition against viruses such as HBV.
Smart Images

Figure PCTCN2024091851-FTAPPB-I100001 
Figure PCTCN2024091851-FTAPPB-I100002 
Figure PCTCN2024091851-FTAPPB-I100003
Abstract
Description
A novel targeting compound and nucleic acid conjugate, and uses thereof Technical Field
[0001] The present invention belongs to the field of drug delivery. The purpose of the present invention is to provide a novel targeting compound and nucleic acid conjugate and their uses. It also relates to a novel conjugate group, which is used for the delivery of small nucleic acid drugs (such as siRNA, ASO, etc.). It can be conjugated with nucleotides to form a nucleic acid conjugate. The nucleotide conjugate is used to regulate gene expression in hepatocytes to prevent and / or treat related diseases. Background Art
[0002] RNA interference (RNAi) is a phenomenon in which double-stranded RNA (dsRNA) molecules shut down or silence homologous gene expression at the mRNA level. RNAi, also known as gene knockdown or gene silencing, is a typical post-transcriptional gene regulation method, also known as post-transcriptional gene silencing (PTGS). The earliest reports of RNAi appeared in 1990, when two different research groups simultaneously reported RNAi in transgenic plants. Subsequently, RNAi was observed in nearly all eukaryotic organisms, including nematodes, fruit flies, zebrafish, and mice. In 1999, Hamilton and Baulcombe detected RNA fragments of 21-25 nucleotides in plants that exhibited RNAi. These RNA fragments were shown to be essential for RNAi and were termed small interfering nucleic acids (siRNAs). Double-stranded siRNAs form an RNA-induced silencing complex (RISC) with relevant cell-derived enzymes and proteins. During RNA interference, the sense strand in the double-stranded siRNA is excluded from the complex, and the antisense strand guides RISC to bind to the homologous site of the target mRNA. The target mRNA is then degraded by ribonuclease III in the complex, thereby shutting down the expression of the target gene.
[0003] The effective delivery of RNAi agents to cells in vivo requires specific targeting and substantial protection against the extracellular environment (particularly serum proteins). One method for achieving specific targeting is to conjugate a targeting moiety (also called conjugation) to the RNAi agent. The targeting moiety helps target the RNAi agent to the desired target site. One way in which the targeting moiety can improve delivery is through receptor-mediated endocytosis activity. The mechanism of this uptake includes the internal movement of the RNAi agent bound to a membrane receptor to a region, which is surrounded by the region by the invagination of the membrane structure or by fusion of the delivery system with the cell membrane. This process is initiated by the activation of the cell surface or membrane receptor after a specific ligand is bound to the receptor.
[0004] In recent years, the use of N-acetylgalactosamine (GalNAc), a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), as a targeting molecule has achieved promising results in liver-targeted delivery of nucleic acid drugs. Patent application WO2009073809A2 discloses oligonucleotide conjugates containing three clusters of N-acetylgalactosamine (GalNAc), in which the GalNAc-containing fragment is linked to the oligonucleotide via 3-hydroxy-5-hydroxymethylpyrrolidine. These conjugates have the ability to inhibit the expression of corresponding genes in cells.
[0005] Summary of the Invention
[0006] The present invention provides a new targeting compound that can be used to prepare a nucleic acid conjugate drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a new targeting conjugate group (i.e., a carrier) that can effectively deliver oligonucleotides to liver cells. The present invention also provides a nucleotide conjugate, a preparation method and an application thereof, which has a high in vivo delivery efficiency, good stability, high gene expression inhibition activity in hepatocytes and / or low toxicity. On the other hand, the present invention further provides an siRNA reagent, a preparation method and an application thereof, which has a high in vivo delivery efficiency, good stability, high gene expression inhibition activity and / or low toxicity against HBV.
[0007] In one aspect, the present invention relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0008] wherein Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms;
[0009] Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2)j C(=O)- or MC(=O)(CH2) j C(=O)-;
[0010] M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG;
[0011] Each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0012] R is a structure represented by the following formula (a) or formula (b):
[0013] Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12 、X 13 、X 14 and X 15 are independently H or a hydroxyl protecting group; each Y1, Y2, Y3, Y4, Y5 is independently H or an amino protecting group;
[0014] Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0015] Each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0016] Each R 1 are independently H, deuterium or C 1-6 alkyl;
[0017] wherein each j is independently 1, 2, 3, 4 or 5;
[0018] Each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0019] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-101, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0020] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0021] In some embodiments of the compounds of the present invention, each of B1, B2, B3, B4 and B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1)-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0022] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)- or MC(=O)(CH2) j C(=O)-, wherein the hydroxyl protecting group is an ester protecting group, an alkoxyalkyl protecting group, a silyl protecting group, a substituted or unsubstituted aryl protecting group, a substituted or unsubstituted arylalkyl protecting group (such as triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.), wherein each M and j has the meaning described in the present invention.
[0023] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylmethyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described herein;
[0024] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0025] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylmethyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described herein;
[0026] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0027] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylmethyl, C1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described herein;
[0028] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0029] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylmethyl, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described herein;
[0030] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0031] In some embodiments of the compounds of the present invention, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X11 、X 12 、X 13 、X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-;
[0032] Each of Y1, Y2, Y3, Y4 and Y5 is independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-;
[0033] Among them, each R 2 and R 3 Independently C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl;
[0034] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0035] Each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0036] In some embodiments of the compounds of the present invention, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X12 、X 13 、X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-;
[0037] Each of Y1, Y2, Y3, Y4 and Y5 is independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-;
[0038] Among them, each R 2 and R 3 Independently C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl;
[0039] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0040] Each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0041] In some embodiments of the compounds of the present invention, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12、X 13 、X 14 and X 15 H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-;
[0042] Each of Y1, Y2, Y3, Y4, and Y5 is H, 9-fluorenylmethoxycarbonyl, or R 3 C(=O)-;
[0043] Among them, each R 2 and R 3 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl;
[0044] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0045] Each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 1-4 Alkenyl or C 1-4 Heteroalkyl.
[0046] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a-1) or formula (b-1):
[0047] (b-1), wherein each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12 、X 13 、X 14 、X 15 , Y1, Y2, Y3, Y4, Y5, A1, A2, A3, A4, A5, B1, B2, B3, B4, B5, C1, C2, C3, C4 and C5 have the meanings described in the present invention.
[0048] In some embodiments, the compound of the present invention has a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II).
[0049] Wherein, the definitions of Z, Y, L1, L2, L3 and R have the meanings described in the present invention.
[0050] In some embodiments, the compound of the present invention has a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III).
[0051] Formula (III) wherein each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ;
[0052] each of F1, F2, and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl;
[0053] Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4,
[0054] Among them, each R 1 、X7、X8、X9、X 10、X 11 、X 12 、X 13 、X 14 、X 15 , Y3, Y4, Y5, Z and Y have the meanings described in the present invention.
[0055] On the other hand, the present invention relates to a conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia),
[0056] Among them, R x It is a structure of formula (c) or formula (d):
[0057] wherein Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms;
[0058] Each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0059] Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1)-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0060] Each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-;
[0061] Each R 1 are independently H, deuterium or C 1-6 alkyl;
[0062] Each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0063] In some embodiments of the conjugate group of the present invention, each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1)-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0064] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0065] In some embodiments of the conjugate group of the present invention, each of B1, B2, B3, B4 and B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0066] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopentyl, pyrrolyl, furyl or piperidinyl group.
[0067] In some embodiments of the conjugated groups of the present invention, the ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl. In some embodiments of the conjugated groups of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl;
[0068] Each R w1 、R w2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0069] In some embodiments of the conjugate group of the present invention, R x It is a structure represented by the following formula (c-1) or formula (d-1):
[0070] (d-1), wherein A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4 and Y5 have the meanings described in the present invention.
[0071] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a),
[0072] Among them, each R x The definitions of L1, L2 and L3 have the meanings described in the present invention.
[0073] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a),
[0074] wherein each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ;
[0075] each of F1, F2, and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl;
[0076] Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4;
[0077] The definitions of R1, Y3, Y4 and Y5 have the meanings described in the present invention.
[0078] In another aspect, the present invention relates to a nucleic acid conjugate comprising the conjugated group of the present invention and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid.
[0079] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is linked to the conjugated group via a phosphate group, a phosphorothioate group, or a phosphate group.
[0080] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, more preferably to the 3' end of the sense strand of the siRNA.
[0081] In some embodiments of the nucleic acid conjugates of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
[0082] On the other hand, the present invention also relates to an siRNA nucleic acid conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255,
[0083] DAW30223:
[0084] Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40002-4 (SEQ ID NO: 2)
[0085] Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7)
[0086] DAW30062:
[0087] Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40003-4 (SEQ ID NO: 3)
[0088] Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7)
[0089] DAW30219:
[0090] Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40004-4 (SEQ ID NO: 4)
[0091] Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7)
[0092] DAW30221:
[0093] Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40005-4 (SEQ ID NO: 5)
[0094] Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7)
[0095] DAW30222:
[0096] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40007-4 (SEQ ID NO: 6)
[0097] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0098] DAW30255:
[0099] Sense strand (5'-3'): gs-us-cauc-Cf-a-Cf-Af-Af-ugagaguaca-DAW40007-4 (SEQ ID NO: 8)
[0100] Antisense strand (5'-3'): us-Gfs-uac-(Tgn)-cucauug-Uf-g-Gf-auga-cs-gs-a (SEQ ID NO: 9)
[0101] Among them, the conjugate groups DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are each conjugated to the 3' end of the siRNA sense strand via a phosphate group, and their structures are shown below:
[0102] In another aspect, the present invention relates to a pharmaceutical composition comprising the siRNA conjugate of the present invention and a pharmaceutically acceptable carrier.
[0103] On the other hand, the present invention also relates to use of the compound, the conjugated group or the nucleic acid conjugate of the present invention in the preparation of a medicament for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in hepatocytes.
[0104] In some embodiments, the present invention also relates to the use of the compound or the conjugated group of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0105] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of small nucleic acid drugs in vivo.
[0106] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of siRNA drugs or ASO drugs in vivo.
[0107] In some embodiments, the present invention also relates to the use of the nucleic acid conjugates of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0108] In another aspect, the present invention relates to the compound of the present invention and the conjugate group for use in the delivery of drugs for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in liver cells.
[0109] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0110] In another aspect, the present invention relates to the use of the nucleic acid conjugate of the present invention for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0111] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0112] In another aspect, the present invention relates to the siRNA drugs DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof for treating and / or preventing hepatitis B disease.
[0113] In another aspect, the present invention relates to the use of DAW30255 or a composition thereof for treating and / or preventing hypertension.
[0114] In another aspect, the present invention relates to a method for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes, which comprises using the compound or the conjugated group of the present invention as a drug delivery system.
[0115] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0116] In yet another aspect, the present invention relates to a method for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in hepatocytes, the method comprising administering the nucleic acid conjugate of the present invention.
[0117] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0118] In another aspect, the present invention relates to a method for preventing, managing, treating or alleviating hepatitis B disease or hypertension, comprising administering to a patient an effective therapeutic amount of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof.
[0119] In another aspect, the present invention relates to a method for preventing, managing, treating or alleviating hepatitis B disease or hypertension, comprising administering to a patient a therapeutically effective amount of DAW30255 or a composition thereof.
[0120] In some embodiments of the present invention, the nucleic acid (or small nucleic acid) of the present invention refers to siRNA or ASO.
[0121] In some embodiments of the use of the present invention, the specific gene is selected from, but not limited to: ApoB, ApoC3 (apolipoprotein C-III encoded by the human apolipoprotein C-III gene), AGT (angiotensinogen), ANGPTL3 (angiopoietin-like 3), PCSK9, LPA (lipoprotein (a)), SCD1, FVII, p53, HBV (hepatitis B virus) or HCV (hepatitis C virus).
[0122] In another aspect, the present invention also relates to the use of DAW30223, DAW30062, DAW30219, DAW30221, and / or DAW30222 described herein, and compositions comprising DAW30223, DAW30062, DAW30219, DAW30221, and / or DAW30222 described herein and a pharmaceutically acceptable carrier, in the preparation of a medicament for treating and / or preventing hepatitis B. In another aspect, the present invention also relates to the use of DAW30255 described herein, or a composition thereof, in the preparation of a medicament for treating and / or preventing hypertension.
[0123] Detailed description of the present invention
[0124] Definitions and General Terms
[0125] In the present invention, the term "comprise" or "include" is an open expression, that is, it includes the content specified in the present invention, but does not exclude other aspects of the content.
[0126] In the present invention, the term "small interfering RNA (siRNA)" refers to a double-stranded RNA of 17 to 30 nucleotides in length, comprising a sense strand and an antisense strand. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming an RNA-induced silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins. For example, siRNA can regulate (e.g., inhibit) the expression of hepatitis B virus in cells.
[0127] In the present invention, the term "antisense strand (or guide strand)" includes a region that is substantially complementary to a target sequence, such as the mRNA of hepatitis B virus. "Sense strand (or follower strand)" refers to an iRNA chain that is substantially complementary to the antisense strand. The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary to the target sequence or at least partially complementary. In the case of partial complementarity, mismatches can exist in the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist in the terminal regions, for example, within 5, 4, 3 or 2 nucleotides of the 5'- and / or 3'-end of the iRNA.
[0128] It should be noted that "at least a portion of the antisense strand is substantially complementary to an mRNA" means that the antisense strand comprises a polynucleotide that is substantially complementary to a continuous portion of an mRNA of interest (e.g., an mRNA encoding hepatitis B virus). Alternatively, if a polynucleotide is substantially non-interruptedly complementary to a portion of an mRNA encoding hepatitis B virus, then the antisense strand is complementary to at least a portion of the hepatitis B virus mRNA.
[0129] In the present invention, the term "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during transcription of a gene encoding hepatitis B virus, including mRNA that is an RNA processing product of a primary transcription product.
[0130] In the present invention, the term "inhibiting the expression of hepatitis B virus genes" includes any level of inhibition of hepatitis B virus (HBV) genes, for example, at least partial inhibition of HBV gene expression, such as inhibition of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%. The expression of HBV genes can be evaluated based on the level of any variable related to HBV gene expression, for example, HBV mRNA level or HBV protein level. Inhibition can be evaluated by the reduction of the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level utilized in this area, for example, a baseline level before administration, or a level determined from a similar subject, cell or sample that has never been treated or treated with a control (e.g., a control or no active agent control using only a buffer).
[0131] In the present invention, "pharmaceutical composition" can refer to a composition used for treating a disease or for in vitro cell culture experiments. When used for treating a disease, the term "pharmaceutical composition" generally refers to a unit dosage form and can be prepared by any method well known in the pharmaceutical art. All methods include the step of combining the active ingredient with an excipient that constitutes one or more auxiliary ingredients. Typically, the composition is prepared by uniformly and thoroughly combining the active siRNA with a liquid excipient, a finely divided solid excipient, or both.
[0132] In the present invention, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal to be treated therewith. Preferably, the "pharmaceutically acceptable" herein means approved by federal regulatory agencies or national governments or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, particularly humans.
[0133] In the present invention, the term "pharmaceutically acceptable excipient" includes any solvent, solid excipient, diluent, or other liquid excipient, etc., suitable for the specific target dosage form. Except to the extent that any conventional excipient is incompatible with the RNAi (e.g., siRNA) of the present invention, for example, by producing any adverse biological effects or interacting in a deleterious manner with any other component of the pharmaceutically acceptable composition, their use is also contemplated by the present invention.
[0134] In addition to any conventional excipients, to the extent that they are incompatible with the RNAi (e.g., siRNA) of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present invention.
[0135] As used herein, the term "treatment" refers to any agent used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug, RNAi agent or siRNA to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing an RNAi agent, siRNA or siRNA conjugate described herein to an individual in need.
[0136] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, A, and T represent the base composition of nucleotides. In the present invention, a, g, c, and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMe C, and 2'-OMe U, respectively; Af, Cf, Gf, and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G, and 2'-fluoro U, respectively; s indicates that the nucleotide has a 5'-phosphorothioate modification; Agn (i.e., GNA) is an adenosine-diol nucleic acid, and Tgn represents a thymine-diol nucleotide residue, whose structure is
[0137] In the context of the present invention, Bz represents benzoyl; MMTr represents 4'-methoxytrityl; DMTr represents 4',4'-dimethoxytriphenylmethyl.
[0138] In the present invention, "phosphate group," "phosphate group," and "phosphate bond" are used interchangeably to include monoesters, phosphodiesters, or phosphotriesters. The "phosphate group" in "phosphorothioate group" also has the same meaning. Unless otherwise specified, the phosphate group between natural nucleotides is a phosphodiester group.
[0139] The term "oxo" refers to a =0 group, for example, a carbon atom connected to an oxygen atom via a double bond, whereby a ketone or aldehyde group is formed.
[0140] As used herein, "chemically modified" or "modification" means a structure that is chemically different when compared to a naturally occurring counterpart, including all changes by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0141] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. Compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0142] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and the pure enantiomers are recovered. In addition, separation of enantiomers and diastereomers is typically accomplished by using chromatography using a chiral stationary phase, optionally combined with chemical derivatization (e.g., carbamate formation from an amine).
[0143] The present invention also includes isotopically labeled compounds of the invention which are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C, 13C, 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.
[0144] Unless otherwise stated, when a position is particularly designated as deuterium (D), the position should be understood to have at least 1000 times the abundance of deuterium greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 10% deuterium incorporation). In the example, the compound has at least 1000 times the abundance of deuterium, at least 2000 times the abundance of deuterium, at least 3000 times the abundance of deuterium, at least 4000 times the abundance of deuterium, at least 5000 times the abundance of deuterium, at least 6000 times the abundance of deuterium or more abundant deuterium. The present invention also includes various deuterated forms of formula (I) compounds. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of formula (I) compounds with reference to relevant literature. In preparing deuterated forms of compounds of formula (I), commercially available deuterated starting materials may be used, or they may be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane, deuterated iodomethane, and the like.
[0145] The conjugated groups of the present invention can enhance the delivery of therapeutic agents to specific target locations (e.g., specific organs or tissues) within a subject such as a human or animal. In some embodiments of the present invention, the conjugated groups can enhance the targeted delivery of expression-inhibitory oligonucleotides. In some embodiments of the present invention, the conjugated groups can enhance the delivery of expression-inhibitory oligonucleotides to the liver.
[0146] The conjugated groups described herein can be directly or indirectly connected to a compound, such as a therapeutic agent, for example, an expression inhibitory oligonucleotide, for example, the 3' or 5' end of an expression inhibitory oligonucleotide. In some embodiments of the present invention, the expression inhibitory oligonucleotide comprises one or more modified nucleotides. In some embodiments of the present invention, the expression inhibitory oligonucleotide is an RNAi agent, such as a double-stranded RNAi agent comprising a sense strand and an antisense strand. In some embodiments of the present invention, the conjugated groups disclosed herein are connected to the 3' end of the sense strand of the double-stranded RNAi agent. In some embodiments, the conjugated groups disclosed herein are connected to the expression inhibitory oligonucleotide agent at the 3' end of the sense strand of the double-stranded RNAi agent via a phosphate, phosphorothioate or phosphonate group.
[0147] Unless otherwise indicated, "conjugation" refers to the covalent linkage of two or more chemical moieties, each with a specific function, to each other; accordingly, "conjugate" refers to a compound formed by covalent linkage of the chemical moieties.
[0148] The double-stranded siRNA conjugate of the present invention is a compound formed by connecting the double-stranded siRNA and a pharmaceutically acceptable conjugated group, and the double-stranded siRNA and the pharmaceutically acceptable conjugated group are covalently linked.
[0149] The definitions and conventions of stereochemistry used herein are generally those of S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist as different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefix D, L or R, S is used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d, l, or (+), (-) are used to designate the sign of rotation of plane-polarized light in a compound. (-) or l means the compound is levorotatory, and the prefix (+) or d means the compound is dextrorotatory. These stereoisomers have the same chemical structure, but their stereostructures are different. Specific stereoisomers can be enantiomers, and a mixture of isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in a lack of stereoselectivity or stereospecificity during chemical reactions. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lacks optical activity.
[0150] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (i.e., prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations.
[0151] The term "composition" refers to a mixture of one or more compounds described herein, or their physiologically acceptable salts or precursors, with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0152] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the U.S. Food and Drug Administration as acceptable for use in humans or domestic animals.
[0153] Unless otherwise specified, the "compound," "ligand," "nucleic acid ligand conjugate," and "nucleic acid" of the present invention may independently exist in the form of a salt, a mixed salt, or a non-salt form (e.g., a free acid or a free base). When present in the form of a salt or a mixed salt, it may be a pharmaceutically acceptable salt.
[0154] The term "acceptable salt" includes acceptable acid addition salts and pharmaceutically acceptable base addition salts. "Acceptable acid addition salts" refers to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, octanoates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamate, pyroglutamate, aspartate, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbate, salicylates, 4-aminosalicylates, and naphthalene disulfonates. These salts can be prepared by methods known in the art.
[0155] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts, with sodium salts being preferred. Salts derived from organic bases include, but are not limited to, following salts: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0156] As described herein, the compounds of the present invention may optionally be substituted with one or more substituents, as described above for the general formula compounds, or as described in the specific examples, subclasses, and classes of compounds encompassed by the present invention. Generally, the term "substituted" refers to the replacement of one or more hydrogen atoms in a given structure with a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given formula can be substituted with one or more substituents selected from a specified group, the substituents may be the same or different at each position.
[0157] In addition, it should be noted that, unless otherwise explicitly stated, the descriptions used throughout this document, “each ... and ... are independently,” “... and ... are each independently,” and “... and ... are respectively independently,” are interchangeable and should be understood in a broad sense. They may mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.
[0158] In the present invention, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur.
[0159] In various parts of this specification, substituents of compounds disclosed herein are disclosed in terms of group types or ranges. It is specifically noted that the present invention includes every independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl as disclosed independently.
[0160] The term "alkyl" as used herein includes saturated linear or branched monovalent hydrocarbon groups of 1 to 20 carbon atoms, wherein the alkyl group may be independently and optionally substituted with one or more substituents described herein. In some embodiments, the alkyl group contains 1 to 12 carbon atoms, in other embodiments, the alkyl group contains 1 to 10 carbon atoms, in other embodiments, the alkyl group contains 1 to 8 carbon atoms, in other embodiments, the alkyl group contains 1 to 6 carbon atoms, in other embodiments, the alkyl group contains 1 to 4 carbon atoms, and in other embodiments, the alkyl group contains 1 to 3 carbon atoms. Further examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), 2-methylpropyl or isobutyl (i-Bu, -CH2CH(CH3)2), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH3)CH2C H3), tert-butyl (t-Bu, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2 -Methyl-1-butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3) , 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, n-nonyl, n-heptanyl, and the like.
[0161] The term "alkylene" refers to a saturated divalent or polyvalent hydrocarbon radical resulting from removing two carbon atoms from a saturated straight or branched hydrocarbon radical. Unless otherwise specified, an alkylene group contains 1 to 12 carbon atoms. In some embodiments, an alkylene group contains 1 to 6 carbon atoms; in other embodiments, an alkylene group contains 1 to 4 carbon atoms; in still other embodiments, an alkylene group contains 1 to 3 carbon atoms; and in still other embodiments, an alkylene group contains 1 to 2 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), isopropylene (-CH(CH3)CH2-), n-propylene (-CH2CH2CH2-), n-butylene (-CH2CH2CH2CH2-), sec-butylene (s-Bu, -CH(CH3)CH2CH2-), n-pentylene (-CH2CH2CH2CH2CH2-), 2-pentylene (-CH(CH3)CH2CH2CH2-), n-hexylene (-CH2CH2CH2CH2CH2CH2-), 2-hexyl (-CH(CH3)CH2CH2CH2CH2-), n-heptylene (-(CH2)7-), n-octylene (-(CH2)8-), n-nonylene (-(CH2)9-), hexylene (-(CH2) 10 -), -(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -,etc.
[0162] The term "heteroalkyl" as used herein refers to an alkyl group having 1, 2, 3, 4, 5 or 6 heteroatoms inserted therein, wherein the heteroatoms are selected from S, N, NH, O or P, and the sulfur atom may be optionally oxidized to S-oxide. In some embodiments, the heteroalkyl group contains 1 to 12 carbon atoms, in other embodiments, the heteroalkyl group contains 1 to 10 carbon atoms, in other embodiments, the heteroalkyl group contains 1 to 8 carbon atoms, in other embodiments, the heteroalkyl group contains 1 to 6 carbon atoms, in other embodiments, the heteroalkyl group contains 1 to 4 carbon atoms, and in other embodiments, the heteroalkyl group contains 1 to 3 carbon atoms. Examples of heteroalkyl groups include, but are not limited to, CH3O-, CH3CH2O-, CH3CH2CH2O-, CH3CH2CH2CH2O-, CH3CH2OCH2-, CH3OCH2CH2OCH2-, CH3CH2OCH2CH2-, CH3OCH2CH2CH2-, CH3S-, CH3CH2S-, CH3CH2CH2S-, CH3CH2CH2CH2S-, CH3CH2SCH2-, CH3SCH2CH2-, CH3CH2CH2SCH2-, CH3CH2SCH2CH2-, CH3SCH2CH2CH2-, CH3NH-, CH3CH2NH-, CH3CH2CH2NH-, CH 3CH2CH2CH2NH-, CH3CH2NHCH2-, CH3NHCH2CH2-, CH3CH2CH2NHCH2-, CH3CH2NHCH2CH2-, CH3NHCH2CH2CH2-, etc.
[0163] The term "alkoxy" refers to an alkyl group attached to the remainder of a molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-8 carbon atoms; in other embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; and in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein.
[0164] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH 3)CH2CH3), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.
[0165] The term "alkenyl" refers to a linear or branched monovalent, divalent or polyvalent hydrocarbon radical containing 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, wherein at least one position of CC is sp 2 Double bond, wherein the alkenyl group can be independently unsubstituted or substituted with one or more substituents described in the present invention, including "cis", "trans" or "Z", "E" isomers, specific examples of which include, but are not limited to, vinyl (-CH=CH2), propenyl (-CH=CHCH3), allyl (-CH2CH=CH2) and the like, wherein the alkenyl group can be independently unsubstituted or substituted with one or more substituents described in the present invention.
[0166] The term "alkynyl" refers to a linear or branched monovalent or divalent hydrocarbon group of 2 to 12 carbon atoms, wherein at least one C—C is an sp triple bond, wherein the alkynyl group may be independently and optionally substituted with one or more substituents described herein. In some embodiments, the alkynyl group contains 2 to 12 carbon atoms, in other embodiments, the alkynyl group contains 2 to 8 carbon atoms, in other embodiments, the alkynyl group contains 2 to 6 carbon atoms, and in other embodiments, the alkynyl group contains 2 to 4 carbon atoms. Specific examples include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH2C≡CH), propynyl (-C≡C-CH3), butyl alkynyl (-CH2CH2C≡CH, -CH2C≡CCH3, -C≡CCH2CH3 and -CH(CH3)C≡CH) and pentynyl (-CH2CH2CH2C≡CH, -CH2CH2C≡CCH3, -CH2C≡CCH2CH3, -C≡CCH2CH2CH3, -CH2CH(CH3)C≡CH, -CH(CH3)CH2C≡CH), -C(CH3)2C≡CH, -CH(CH3)C≡CCH3, -C≡CCH(CH3)CH3 and -C≡CCH(CH3)2), and the like.
[0167] The term "cycloalkyl" refers to a monovalent or multivalent saturated monocyclic, bicyclic, or tricyclic ring system containing 3 to 12 carbon atoms. In one embodiment, the cycloalkyl group contains 3 to 12 carbon atoms; in another embodiment, the cycloalkyl group contains 3 to 8 carbon atoms; in another embodiment, the cycloalkyl group contains 3 to 7 carbon atoms; and in yet other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms. Examples of cycloalkyl groups further include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
[0168] The term "consisting of M-M1 ring atoms" means that the cyclic group is composed of M-M1 ring atoms, wherein the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P. For example, "a heterocyclic group consisting of 3-6 ring atoms" means a monoheterocyclic group consisting of 3, 4, 5, or 6 ring atoms.
[0169] The term "heterocyclyl" refers to a non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur or oxygen atoms. The heterocyclyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the heterocyclyl group may be carbonyl or nitrogenyl, and the -CH2- group may be optionally replaced by -C(=O)- or -C(=S)-. The sulfur atom of the ring may be optionally oxidized to an S-oxide. The nitrogen atom of the ring may be optionally oxidized to an N-oxide. In some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3-12 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5-10 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3-6 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 4-6 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5-6 ring atoms, in other embodiments, the heterocyclyl group is a heterocyclyl group consisting of 4 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 4 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 5 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 6-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 6 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. "Heterocyclic group" also includes groups formed by condensing a heterocyclic group with a saturated or partially unsaturated ring or heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, glycidyl, azepanyl, oxetanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3- pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazolinyl, dithianyl, dithiolanyl, dihydrothienyl, pyrazolidinylimidazolinyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 3H-indolylquinolizinyl and N-pyridylurea.Examples of heterocyclic groups also include 1,1-dioxothiomorpholinyl, examples of which the ring carbon atoms are replaced by oxo (=O) include, but are not limited to, pyrimidinedione, 1,2,4-thiadiazole-5(4H)-one, 1,2,4-oxadiazole-5(4H)-one, 1H-1,2,4-triazole-5(4H)-one, and the like, examples of which the ring carbon atoms are replaced by a group =S include, but are not limited to, 1,2,4-oxadiazole-5(4H)-thione, 1,3,4-oxadiazole-2(3H)-thione, and the like.
[0170] The term "heteroatom" refers to one or more O, S, N, P and Si, including N, S and P in any oxidation state; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring in which the hydrogen is substituted, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl, wherein R represents a substituent as described herein).
[0171] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbon ring system containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system comprises a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups include phenyl, naphthyl, and anthracenyl. The aryl groups can be independently and optionally substituted with one or more substituents described herein.
[0172] The terms "alkylsilyl" and "alkylsilyl" refer to silyl (-SiH3) groups in which the hydrogen atoms are independently replaced by 1, 2, or 3 alkyl groups. In some embodiments, the alkylsilyl group is 1, 2, or 3 C 1-12 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-9 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-6 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-4 Alkyl groups are lower alkylsilyl groups formed by connecting an alkyl group to a silicon atom. In still other embodiments, an alkylsilyl group is 1, 2 or 3 C 1-3An alkyl group is a lower alkylsilyl group formed by connecting an alkyl group to a silicon atom. Suitable alkylsilyl groups can be monoalkylsilyl, dialkylsilyl or trialkylsilyl. Examples of alkylsilyl groups include, but are not limited to, trimethylsilyl (-Si(CH3)3), triethylsilyl (-Si(CH2CH3)3), tri-n-propylsilyl (-Si(CH2CH2CH3)3), and the like.
[0173] The term "hydroxy protecting group" refers to an unstable chemical moiety that protects the hydroxyl group from undesirable reactions during one or more synthesis procedures. After the one or more synthesis procedures, the hydroxy protecting group can be selectively removed. Hydroxy protecting groups as known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxy protecting groups of the present invention include, but are not limited to, C 1-10 alkylmethyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl (Ac or -C(O)CH3), formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl (Bz or -C(O)C6H5), C 1-10 Alkyl (methyl, tert-butyl, etc.), 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, C 6-10 Aryl C 1-4 Alkyl (such as benzyl, phenethyl, etc.), p-methoxybenzyldiphenylmethyl, triphenylmethyl (triphenylmethyl or trityl), tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, C 1-10 Alkylsilyl (such as trimethylsilyl (TMS or -Si(CH3)3)), triethylsilyl, triisopropylsilyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.
[0174] The term "amino protecting group" refers to an unstable chemical moiety that protects the amino group from undesirable reaction during the building-up sequence. After the one or more building-up sequences, the amino protecting group as described herein can be selectively removed. Amino protecting groups as known in the art are generally described in TH Greene and PGM Woods, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons, New York (1999). The example of amino protecting groups includes but is not limited to acetyl, tert-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl and benzyloxycarbonyl etc.
[0175] Term " solid phase support " specifically represents any particle, pearl or the surface on which oligonucleotide synthesis can occur.For example inorganic solid phase support and organic solid phase support, all can be selected for use in embodiments of the present invention.Inorganic solid phase support is preferably selected from silica gel and controlled pore glass beads (Controlled-pore glass is called for short CPG).Organic solid phase support is a resin, preferably macroporous resin, more preferably highly cross-linked polystyrene, Tentagel (graft copolymer made up of low cross-linked polystyrene matrix, polyethylene glycol (PEG or POE) is grafted thereon), polyvinyl acetate (PVA), copolymer, aminopolyethylene glycol and cellulose etc. of Bo Luosi (Poros)-polystyrene / divinylbenzene.Preferred embodiments of the present invention utilize solid phase support based on CPG.Many other purchasable solid phase supports all belong to the present invention.
[0176] Unless otherwise specified, A1, A2, A3, A4, A5, C1, C2, C3, C4, B1, B2, B3, B4, B5, C5, Y1, Y2, Y3, Y4, Y5, L1, L2, F1, F2, F3, L3, D1, D2 and D3 involved in the general formula of the present invention are divalent linking groups; Ring A is a trivalent linking group.
[0177] When the Markush variables involved in the general formulas of the present invention need to be used as linking groups, the groups listed for the Markush variables should be understood as linking groups. For example, A1, A2, A3, A4, A5, C1, C2, C3, C4, B1, B2, B3, B4, B5, C5, Y1, Y2, Y3, Y4, Y5, L1, L2, F1, F2, F3, L3, D1, D2 and D3 in the general formulas of the present application should be understood as linking groups, and the linking groups involved, such as "cycloalkyl", "heterocyclyl", "heteroalkyl", "alkenyl" and "alkynyl" should respectively represent divalent linking groups such as "cycloalkylene", "heterocyclylene", "heteroalkylene", "alkenylene" and "alkynylene". Description of the drawings:
[0178] FIG1 is a graph showing the inhibitory effects of the siRNA conjugates DAW30221, DAW30222 and DAW30223 of the present invention and the control conjugate DAW30025 on HBsAg in a Tg / HBV mouse model experiment.
[0179] FIG2 is a curve diagram showing the knockdown effect of the siRNA conjugate DAW30255 of the present invention on AGT in a mouse model experiment.
[0180] Detailed description of the compounds of the present invention
[0181] The present invention provides a novel targeting compound that can be used to prepare a nucleic acid drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a nucleotide conjugate, a method for its preparation, and its use, which exhibits high in vivo delivery efficiency, good stability, high gene expression inhibition activity in hepatocytes, and / or low toxicity. In yet another aspect, the present invention further provides an siRNA reagent, a method for its preparation, and its use, which exhibits high in vivo delivery efficiency, good stability, high gene expression inhibition activity in HBV, and / or low toxicity.
[0182] In one aspect, the present invention relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0183] wherein Z, Y, ring A, L1, L2, L3 and R have the meanings as defined in the present invention.
[0184] In some embodiments of the compounds of the present invention, Ring A is a heterocyclyl consisting of 3 to 12 atoms or a cycloalkyl consisting of 3 to 12 atoms.
[0185] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)- or MC(=O)(CH2) j C(=O)-, wherein each M and j has the meanings described in the present invention.
[0186] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)- or MC(=O)(CH2) jC(=O)-, wherein the hydroxy protecting group is an ester protecting group, an alkoxyalkyl protecting group, a silyl protecting group, a substituted or unsubstituted aryl protecting group, or a substituted or unsubstituted arylalkyl protecting group, wherein each M and j has the meaning described in the present invention.
[0187] In some embodiments of the compounds of the present invention, each j is independently 1, 2, 3, 4 or 5.
[0188] In some embodiments of the compounds of the present invention, M is a solid support.
[0189] In some embodiments of the compounds of the present invention, M is a hydroxyl- or amino-functionalized solid support.
[0190] In some embodiments of the compounds of the present invention, M is a resin or CPG.
[0191] In some embodiments of the compounds of the present invention, M is a macroporous resin or CPG.
[0192] In some embodiments of the compounds of the present invention, M is an aminomethyl resin, a hydroxy resin, or CPG.
[0193] In some embodiments of the compounds of the present invention, M is an aminomethyl resin, a hydroxy resin, an aminoCPG, or a hydroxyCPG.
[0194] In some embodiments of the compounds of the present invention, M is an aminomethyl resin, a hydroxy resin, or -NHCPG.
[0195] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1)-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0196] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a) or formula (b):
[0197] Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12 、X 13 、X 14 、X 15 , Y1, Y2, Y3, Y4, Y5, A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 have the meanings described in the present invention.
[0198] In some embodiments of the compounds of the present invention, wherein each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10 、X 11 、X 12 、X 13 、X 14 and X 15 are independently H or a hydroxy protecting group.
[0199] In some embodiments of the compounds of the present invention, each of Y1, Y2, Y3, Y4 and Y5 is independently H or an amino protecting group.
[0200] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0201] In some embodiments of the compounds of the present invention, each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0202] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0203] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1)S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0204] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1)C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0205] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-41, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0206] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0207] In some embodiments of the compounds of the present invention, each of L1, L2 and L3 is independently -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11-、-(CH2) 12 -、C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0208] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0209] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl or C 2-8 Alkynyl, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1)-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0210] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1)C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0211] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-41, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0212] In some embodiments of the compounds of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolidyl ... pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1)-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1)-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0213] In some embodiments of the compounds of the present invention, each B1, B2, B3, B4 or B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0214] In some embodiments of the compounds of the present invention, each B1, B2, B3, B4 or B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl or C 2-4 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0215] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylmethyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0216] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylmethyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) jC(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0217] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylmethyl, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0218] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylmethyl, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2)j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0219] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl , methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methyl C(=O)-, ethyl C(=O)-, n-propyl C(=O)-, isopropyl C(=O)-, n-butyl C(=O)-, isobutyl C(=O)-, tert-butyl C(=O)-, C 1-4 Alkylmethyl, C 1-4 Alkylsilyl, phenylmethyl, phenylethyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0220] In some embodiments of the compounds of the present invention, the ring A is a heterocyclic group consisting of 3 to 7 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0221] In some embodiments of the compounds of the present invention, the ring A is a heterocyclic group consisting of 3 to 6 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0222] In some embodiments of the compounds of the present invention, Ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0223] In some embodiments of the compounds of the present invention, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12、X 13 、X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-, where R 2 has the meanings described in the present invention.
[0224] In some embodiments of the compounds of the present invention, each of Y1, Y2, Y3, Y4 and Y5 is independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-, where R 3 has the meanings described in the present invention.
[0225] In some embodiments of the compounds of the present invention, each R 2 and R 3 Independently C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.
[0226] In some embodiments of the compounds of the present invention, each R 2 and R 3 Independently C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.
[0227] In some embodiments of the compounds of the present invention, each R 2 and R 3are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, tert-butoxy, 2-methyl-1-propoxy, 2-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.
[0228] In some embodiments of the compounds of the present invention, each R 1 are independently H, deuterium or C 1-6 alkyl.
[0229] In some embodiments of the compounds of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl.
[0230] In some embodiments of the compounds of the present invention, each R 1 is independently H, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
[0231] In some embodiments of the compounds of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0232] In some embodiments of the compounds of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-4 Alkyl, C 1-4 Alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0233] In some embodiments of the compounds of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C2-4 Alkenyl or C 1-4 Heteroalkyl.
[0234] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a-1) or formula (b-1):
[0235] (b-1), wherein each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12 、X 13 、X 14 、X 15 , Y1, Y2, Y3, Y4, Y5, A1, A2, A3, A4, A5, B1, B2, B3, B4, B5, C1, C2, C3, C4 and C5 have the meanings described in the present invention.
[0236] In some embodiments, the compound of the present invention has a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II).
[0237] wherein each of Z, Y, L1, L2, L3 and R has the meanings described in the present invention.
[0238] In some embodiments, the compound of the present invention has a structure as shown in formula (II-1), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II-1).
[0239] wherein each of Z, Y, L1, L2, L3 and R has the meanings described in the present invention.
[0240] In some embodiments, the compound of the present invention has a structure as shown in formula (II-2), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II-2).
[0241] wherein each of Z, Y, L1, L2, L3 and R has the meanings described in the present invention.
[0242] In some embodiments, the compound of the present invention has a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III).
[0243] wherein each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O-* 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ;
[0244] each of F1, F2, and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl;
[0245] Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4,
[0246] Among them, each R 1 、X7、X8、X9、X 10 、X 11 、X 12 、X 13 、X 14 、X 15 , Y3, Y4, Y5, Z and Y have the meanings described in the present invention.
[0247] In some embodiments of the compounds of the present invention, the present invention has one of the compounds shown below, or a stereoisomer, tautomer or acceptable salt thereof,
[0248] M is a solid support, preferably a hydroxyl or amino functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxy resin, an aminoCPG or a hydroxyCPG; further preferably an aminomethyl resin, a hydroxy resin or -NHCPG.
[0249] On the other hand, the present invention relates to a conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia),
[0250] Among them, each ring A, L1, L2, L3 and R x has the meanings described in the present invention.
[0251] In some embodiments of the conjugate group of the present invention, R x It is a structure of formula (c) or formula (d):
[0252] Each A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4 and Y5 have the meanings described in the present invention.
[0253] In some embodiments of the conjugated group of the present invention, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms.
[0254] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3 to 7 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0255] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3 to 6 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0256] In some embodiments of the conjugate group of the present invention, the ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0257] In some embodiments of the conjugate groups of the present invention, each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1)S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0258] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0259] In some embodiments of the conjugate groups of the present invention, each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3 Substitute, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 has the meanings described in the present invention.
[0260] In some embodiments of the conjugate groups of the present invention, each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-101, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0261] In some embodiments of the conjugate groups of the present invention, each of L1, L2 and L3 is independently C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0262] In some embodiments of the conjugate groups of the present invention, each of L1, L2 and L3 is independently C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1)-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0263] In some embodiments of the conjugate groups of the present invention, each of L1, L2 and L3 is independently C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1)C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitute, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0264] In some embodiments of the conjugate group of the present invention, each of L1, L2 and L3 is independently -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12-, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-41, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0265] In some embodiments of the conjugate group of the present invention, each of L1, L2 and L3 is independently -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W1 has the meanings described in the present invention.
[0266] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0267] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl or C 2-8 Alkynyl, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2Substitute, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0268] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0269] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1)C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-6 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2 Substitute, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0270] In some embodiments of the conjugate groups of the present invention, each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolidyl ... pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W2Substitution, each of -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -O(CH2)4NHCH2-, -O(CH2)3NHCH2-, -O(CH2)5NHCH2-, -O(CH2)4NH-, -O(CH2)3NH-, -O(CH2)5NH-, -CH2O(CH2)4NH-, -CH2O(CH2)3NH-, -CH2O(CH2)2NH-, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、 -C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W2 has the meanings described in the present invention.
[0271] In some embodiments of the conjugate groups of the present invention, each B1, B2, B3, B4 or B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl groups are independently optionally substituted with 1, 2, 3 or 4 R W3Substitute, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0272] In some embodiments of the conjugate groups of the present invention, each B1, B2, B3, B4 or B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl or C 2-4 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, each of the cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4Alkynylcyclopropyl is optionally substituted independently by 1, 2, 3 or 4 R W3 Substitute, each C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally replaced by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-, wherein each R 1 and R W3 has the meanings described in the present invention.
[0273] In some embodiments of the conjugate group of the present invention, each R 1 are independently H, deuterium or C 1-6 alkyl.
[0274] In some embodiments of the conjugate group of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl.
[0275] In some embodiments of the conjugate group of the present invention, each R 1 is independently H, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
[0276] In some embodiments of the conjugate group of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0277] In some embodiments of the conjugate group of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-4 Alkyl, C 1-4 Alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0278] In some embodiments of the conjugate group of the present invention, each R W1 、R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0279] In some embodiments of the conjugate group of the present invention, R x It is a structure represented by the following formula (c-1) or formula (d-1):
[0280] (d-1), wherein A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4 and Y5 have the meanings described in the present invention.
[0281] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a),
[0282] Among them, each R x The definitions of L1, L2 and L3 have the meanings described in the present invention.
[0283] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a-1), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a-1),
[0284] Among them, each L1, L2, L3 and R x has the meanings described in the present invention.
[0285] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a-2), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a-2),
[0286] Among them, each L1, L2, L3 and R x has the meanings described in the present invention.
[0287] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a),
[0288] wherein each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ;
[0289] each of F1, F2, and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl;
[0290] Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4,
[0291] Wherein, the definitions of R1, Y1, Y2, Y3, Y4 and Y5 have the meanings described in the present invention.
[0292] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has one of the structures shown below, or a stereoisomer, tautomer or acceptable salt thereof,
[0293] In another aspect, the present invention relates to a nucleic acid conjugate comprising the conjugated group of the present invention and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid.
[0294] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is linked to the conjugated group via a phosphate group, a phosphorothioate group, or a phosphate group.
[0295] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, more preferably to the 3' end of the sense strand of the siRNA.
[0296] In some embodiments of the nucleic acid conjugates of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
[0297] On the other hand, the present invention also relates to an siRNA nucleic acid conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255,
[0298] DAW30223:
[0299] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40002-4 (SEQ ID NO: 2)
[0300] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0301] DAW30062:
[0302] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40003-4 (SEQ ID NO: 3)
[0303] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0304] DAW30219:
[0305] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40004-4 (SEQ ID NO: 4)
[0306] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0307] DAW30221:
[0308] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40005-4 (SEQ ID NO: 5)
[0309] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0310] DAW30222:
[0311] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40007-4 (SEQ ID NO: 6)
[0312] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0313] DAW30255:
[0314] Sense strand (5'-3'): gs-us-cauc-Cf-a-Cf-Af-Af-ugagaguaca-DAW40007-4 (SEQ ID NO: 8)
[0315] Antisense strand (5'-3'): us-Gfs-uac-(Tgn)-cucauug-Uf-g-Gf-auga-cs-gs-a (SEQ ID NO: 9).
[0316] In some embodiments, the conjugate groups DAW40002-4, DAW40003-4, 40004-4, DAW40005-4, and DAW40007-4 of the present invention are each conjugated to the 3' end of the siRNA sense strand via a phosphate group, and have the following structures:
[0317] In another aspect, the present invention relates to a pharmaceutical composition comprising the siRNA conjugate of the present invention and a pharmaceutically acceptable carrier.
[0318] On the other hand, the present invention also relates to the use of the compound, the conjugated group or the nucleic acid conjugate of the present invention in the preparation of a drug for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in liver cells.
[0319] In some embodiments, the present invention also relates to the use of the compound or the conjugated group of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0320] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of small nucleic acid drugs in vivo.
[0321] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of siRNA drugs or ASO drugs in vivo.
[0322] In some embodiments, the present invention also relates to the use of the nucleic acid conjugates of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0323] In some embodiments, the present invention also relates to the use of the compound or the conjugated group of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0324] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of small nucleic acid drugs in vivo.
[0325] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of siRNA drugs or ASO drugs in vivo.
[0326] In some embodiments, the present invention further relates to the use of the nucleic acid conjugates of the present invention in the delivery of drugs for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes. In another aspect, the present invention relates to the use of the conjugate groups of the compounds of the present invention in the delivery of drugs for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0327] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0328] In another aspect, the present invention relates to the use of the nucleic acid conjugate of the present invention for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0329] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0330] In another aspect, the present invention relates to the siRNA drugs DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof for treating and / or preventing hepatitis B disease.
[0331] In another aspect, the present invention relates to the use of DAW30255 or a composition thereof for treating and / or preventing hypertension.
[0332] In another aspect, the present invention relates to a method for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes, which comprises using the compound or the conjugated group of the present invention as a drug delivery system.
[0333] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0334] In yet another aspect, the present invention relates to a method for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in hepatocytes, the method comprising administering the nucleic acid conjugate of the present invention.
[0335] In some embodiments described herein, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0336] In another aspect, the present invention relates to a method for preventing, managing, treating or alleviating hepatitis B disease or hypertension, comprising administering to a patient an effective therapeutic amount of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof.
[0337] In another aspect, the present invention relates to a method for preventing, managing, treating or alleviating hepatitis B disease or hypertension, comprising administering to a patient a therapeutically effective amount of DAW30255 or a composition thereof.
[0338] In some embodiments of the use of the present invention, the specific genes include, but are not limited to, ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0339] In some embodiments of the use of the present invention, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0340] On the other hand, the present invention also relates to the use of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a composition comprising DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a pharmaceutically acceptable carrier in the preparation of a medicament for treating and / or preventing hepatitis B.
[0341] On the other hand, the present invention also relates to the use of DAW30255 or a composition thereof according to the present invention in the preparation of a medicament for treating and / or preventing hypertension.
[0342] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, comprising administering the nucleic acid conjugate or composition thereof of the present invention to the patient, wherein the nucleic acid conjugate or composition thereof may be a therapeutically effective amount.
[0343] In some embodiments of the present invention, the nucleic acid (or small nucleic acid) of the present invention refers to siRNA or ASO.
[0344] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, comprising administering to the patient the siRNA conjugate or a composition thereof of the present invention, wherein the nucleic acid ligand conjugate or the composition thereof can be a therapeutically effective amount.
[0345] Nucleic acid conjugates, preparations, administration and disease treatment methods of the present invention
[0346] The effective amount of the nucleic acid conjugate (such as siRNA conjugate or pharmaceutical composition) of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment condition, several divided doses may be administered daily, for example, at a dosage of four times a day, three times a day, twice a day, once a day, or every other day, or the administration of several doses per day may be proportionally reduced.
[0347] The drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration), preferably intravenous administration.
[0348] The pharmaceutical compositions disclosed herein include formulations suitable for parenteral administration. The formulations can conveniently be presented in unit dosage form and can be prepared by any method known in the pharmaceutical art. The amount of active ingredient that can be combined with excipients to prepare a single dose is generally the amount of siRNA that will produce a therapeutic effect. Generally, in percent units, this amount is from about 1% to about 99% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%.
[0349] In another aspect of the present invention, the present invention provides a method for inhibiting the expression or activity of hepatitis B virus genes. According to an embodiment of the present invention, the method comprises: contacting the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition with cells. As mentioned above, the aforementioned siRNA and siRNA conjugate can both degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the method of the present invention can be used to inhibit the expression or activity of hepatitis B virus genes. For example, the expression or activity of hepatitis B virus genes can be inhibited in animals; or the expression or activity of hepatitis B virus genes can be inhibited for non-disease treatment purposes, such as inhibiting the expression or activity of hepatitis B virus genes in vitro for subsequent research.
[0350] In yet another aspect, the present invention provides a method for preventing and / or treating hepatitis B virus-induced diseases. According to an embodiment of the present invention, the method comprises administering a pharmaceutically acceptable amount of the aforementioned siRNA, siRNA conjugate, or pharmaceutical composition to a subject. According to an embodiment of the present invention, the method can effectively prevent and / or treat diseases associated with hepatitis B virus-induced diseases.
[0351] General synthesis method of the compounds and nucleic acid conjugates of the present invention
[0352] Generally, the compounds and nucleic acid conjugates of the present invention can be prepared by the methods described herein, wherein, unless otherwise specified, the substituents are defined as shown in Formula (I), (II), (II-1), (II-2), (III), (Ia), (II-a), (II-a-1), (II-a-2), (III-a). The following reaction schemes and examples are provided to further illustrate the present invention.
[0353] In the examples described below, all temperatures are in degrees Celsius (°C) unless otherwise indicated. Silica gel (200-300 mesh) was purchased from Qingdao Ocean Chemical Plant, and NH2CPG was purchased from Hebei Dinaxingke. Nuclear magnetic resonance spectra were obtained using CDC13, DMSO-d6, CD3OD, or acetone-d6 as solvents (in ppm), with TMS (0 ppm) or chloroform (7.25 ppm) as the reference standard. When multiple peaks are present, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), br.s (broadened singlet), and q (quartet). Coupling constants, J, are expressed in Hertz (Hz).
[0354] Low-resolution mass spectrometry (MS) data were measured by an Agilent 6320 series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315B DAD detector were used for analysis, and an ESI source was applied to the LC-MS spectrometer.
[0355] High-resolution mass spectrometry (MS) data were determined by an Agilent 6130 series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column temperature maintained at 30 °C). A G1329A autosampler and a G1315D DAD detector were used for analysis, and an ESI source was applied to the HR-MS spectrometer.
[0356] The following abbreviations are used throughout the present invention: EDCI 1-ethyl-3(3-dimethylpropylamine)carbodiimide EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HOBT 1-hydroxybenzotriazole EA ethyl acetate TFA trifluoroacetic acid HOBT 1-hydroxybenzotriazole Py pyridine DMAP 4-dimethylaminopyridine PE petroleum ether MsCl methanesulfonyl chloride ACN acetonitrile TMSOTf trimethylsilyl trifluoromethanesulfonate Ac2O acetic anhydride THF tetrahydrofuran Boc tert-butyloxycarbonyl mL milliliters MeOH methanol min minutes DMSO dimethyl sulfoxide M,N,mol / L moles / liter DMF N,N-dimethylformamide h hours DCM dichloromethane RT,rt room temperature DIPEA N,N-diisopropylethylamine HBTU benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate DETAILED DESCRIPTION
[0357] The scheme of the present invention will be explained below with reference to the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. In particular, the synthesis of small nucleic acids and the synthesis of nucleic acid conjugates can be synthesized according to the embodiments of the present invention or routine adjustments in the art. If specific techniques or conditions are not specified in the examples, they are carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0358] Synthesis method of the compound of the present invention
[0359] The following synthetic schemes list general experimental procedures for preparing the compounds disclosed herein. Those skilled in the art can prepare the compounds of the present invention by making appropriate modifications to the methods or adjusting the starting materials according to actual circumstances. M, X7, X8, X9, D1, F1, n1, Y3, L1, L2, L3, m1, m2, m3, and R have the meanings described herein. Unless otherwise indicated, the compounds of the present invention can be prepared by the methods described in the following synthetic schemes.
[0360] Synthesis Scheme 1:
[0361] The compound represented by formula (A-4) can be prepared by the method described in Synthesis Scheme 1, wherein Q is an amino protecting group, such as Cbz, Boc, etc. Compound (A-1) is subjected to removal of the amino protecting group Q to obtain compound (A-2); compound (A-2) then undergoes a condensation reaction with compound (A-3) to obtain compound (A-4).
[0362] Synthesis Scheme 2:
[0363] The compound represented by formula (a-5) can be prepared by the method described in Synthesis Scheme 2, wherein L1 contains a carbonyl group at one end of the benzyloxy group. The benzyl group of compound (a-1) is removed to obtain compound (a-2); compound (a-2) undergoes a condensation reaction with compound 13 to obtain compound (a-3); compound (a-3) reacts with succinic anhydride to obtain compound (a-4); and compound (a-4) reacts with a solid support to obtain compound (a-5).
[0364] Preparation Example
[0365] In the following preparation examples, the inventors describe in detail the preparation process of the compounds of the present invention using some of the compounds of the present invention as examples, wherein: For CPG.
[0366] Example 1: Compound DAW40003-3
[0367] Step 1: Synthesis of compound 3
[0368] Compound 1 (2.42 g, 19.98 mmol) and sodium hydroxide (0.40 mL, 2.00 mmol) were dissolved in DMSO (4 mL). Compound 2 (8.96 g, 69.93 mmol) was slowly added, and the mixture was stirred at room temperature for 36 h. The solvent was then evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (PE / EA (V / V) = 1 / 2 + 0.05% concentrated aqueous ammonia) to afford compound 3 (4.61 g, 45.64%) as a pale yellow oil. MS (ESI, pos. ion) m / z: 506.4 [M+H] + .
[0369] Step 2: Synthesis of compound 5
[0370] Compound 4 (prepared according to the synthesis method of compound 76 in WO2020093053A1) (0.15 g, 0.47 mmol), HBTU (0.23 g, 0.60 mmol), and DIPEA (0.16 g, 1.20 mmol) were dissolved in DMF (1 mL) and stirred at room temperature for 5 min. Compound 3 (0.20 g, 0.40 mmol) was then added and stirred for 16 h. After the reaction was complete, the mixture was diluted with water (10 mL), extracted with DCM (2 × 50 mL), dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure to obtain a light yellow viscous compound 5 (0.32 g, 100.12%), which was directly used in the next step. MS (ESI, pos.ion) m / z: 404.5 [M / 2+H] + .
[0371] Step 3: Synthesis of compound 6
[0372] Compound 5 (0.30 g, 0.37 mmol) was dissolved in TFA (3 mL) and stirred at room temperature for 3 h. The solvent was evaporated to dryness under reduced pressure, and the product was purified by C18 reverse-phase preparative chromatography (acetonitrile / water (V / V) = 1 / 1 to 5 / 1 + 0.1% TFA) and lyophilized under reduced pressure to obtain compound 6 (0.20 g, 84.21%) as a white solid. MS (ESI, pos. ion) m / z: 640.3 [M+H] + .
[0373] Step 4: Synthesis of compound 8
[0374] Compound 6 (0.15 g, 0.23 mmol), compound 7 (0.15 g, 0.81 mmol), EDCI (0.19 g, 0.97 mmol), and HOBT (0.13 g, 0.97 mmol) were dissolved in DCM (3 mL) and stirred at room temperature for 15 h. The reaction was quenched by the addition of water (5 mL), then diluted with DCM (40 mL). The mixture was washed sequentially with hydrochloric acid solution (20 mL, 1 M), saturated sodium bicarbonate solution (10 mL), and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 10 / 1 to 5 / 1) to give a light yellow viscous compound 8 (0.26 g, 96.81%). MS (ESI, pos. ion) m / z: 1144.7 [M+H] + .
[0375] Step 5: Synthesis of compound 9
[0376] Compound 8 (0.26 g, 0.23 mmol) was dissolved in TFA (5 mL) and stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure to give a pale yellow viscous compound 9 (0.27 g), which was directly used for the next reaction. MS (ESI, pos.ion) m / z: 844.8 [M+H] + .
[0377] Step 6: Synthesis of compound 11
[0378] Compound 10 (0.10 g, 0.23 mmol) (purchased from Lingkai Pharmaceuticals), HBTU (0.33 g, 0.87 mmol), HOBT (0.12 g, 0.87 mmol), and DIPEA (0.30 g, 2.30 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 5 min. A solution of compound 9 (0.27 g) obtained in Step 5 in DMF (1 mL) was then slowly added, and the mixture was stirred at room temperature for 19 h. After the reaction was complete, the mixture was diluted with DCM (100 mL) and washed sequentially with saturated sodium bicarbonate solution (100 mL) and saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 20 / 1 to 5 / 1) to afford compound 11 (0.39 g, 80.42%) as a slightly yellow solid. MS (ESI, pos.ion) m / z: 2131.0 [MH] + .
[0379] Step 7: Synthesis of compound 12
[0380] Compound 11 (0.11 g, 0.052 mmol) and palladium / carbon (0.0055 g, 0.0052 mmol, 10%) were added to methanol (5 mL). The reaction system was replaced with hydrogen three times and then stirred at room temperature under a hydrogen atmosphere for 8 h. After the reaction, the mixture was filtered through celite and the filtrate was evaporated to dryness under reduced pressure to obtain compound 12 (0.10 g, 94.92%) as a yellow-brown oil, which was used directly in the next reaction. MS (ESI, pos. ion) m / z: 2041.0 [MH] - .
[0381] Step 8: Synthesis of compound DAW40003-1
[0382] Compound 12 (0.28 g, 0.14 mmol), HBTU (0.058 g, 0.15 mmol), and DIPEA (0.062 g, 0.48 mmol) were dissolved in DCM (2 mL) and stirred at room temperature for 5 min. Subsequently, a solution of compound 13 (0.059 g, 0.14 mmol) in DCM (1 mL) was slowly added dropwise. The mixture was stirred at room temperature for 12 h. The solvent was evaporated under reduced pressure, and the residue was dissolved in DMF (5 mL) and separated by reverse-phase preparative column chromatography (acetonitrile / water (v / v) = 43% to 49% + 0.1% ammonium acetate). The product-containing solution was saturated with sodium chloride. The organic phase was separated and the aqueous phase was extracted with acetonitrile (2 × 100 mL). The combined organic phases were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to yield compound DAW40003-1 (0.18 g, 53.72%) as a pale yellow solid. MS (ESI, pos.ion) m / z: 2442.0 [MH] - .
[0383] Step 9: Synthesis of compound DAW40003-2
[0384] Under nitrogen, compound DAW40003-1 (0.45 g, 0.19 mmol), succinic anhydride (0.022 g, 0.22 mmol), DMAP (0.032 g, 0.26 mmol), and DIPEA (0.048 g, 0.37 mmol) were dissolved in DCM (2 mL) and stirred at room temperature for 41.5 h. After the reaction, the mixture was diluted with DCM (100 mL) and washed sequentially with saturated sodium bicarbonate solution (20 mL) and saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to yield a pale yellow viscous compound DAW40003-2 (0.19 g, 40.56%), which was used directly in the next reaction. MS (ESI, pos. ion) m / z: 2542.2 [MH] + .
[0385] Step 10: Synthesis of compound DAW40003-3
[0386] Compound DAW40003-2 (0.18 g, 0.071 mmol), HBTU (0.040 g, 0.11 mmol), and DIPEA (0.024 mL, 0.14 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. The mixture was then transferred to a solid-phase synthesizer containing 0.7 g of H2N-CPG (purchased from Hebei Dinaxingke) and shaken for 22.5 h. The filter cake was filtered and rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL), and the filter cake was dried. The filter cake was diluted in 25% Ac2O / Py solution (5 mL) and reacted for 3 h. The reaction was then completed by filtration. The filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in sequence and dried under reduced pressure to give a white solid DAW40003-3 (0.67 g). The loading was measured to be 29.39 μmol / g.
[0387] Example 2: Compound DAW40004-3
[0388] Step 1: Synthesis of compound 17
[0389] Compound 16 (2.00 g, 9.94 mmol) and triethylamine (3.02 g, 29.82 mmol) were dissolved in DCM (20 mL). Methanesulfonyl chloride (1.37 g, 11.93 mmol) was added dropwise to the solution under ice-cooling. The reaction mixture was stirred at room temperature for 31 h. After the reaction was complete, DCM (100 mL) and dilute hydrochloric acid (0.2 M, 20 mL) were added sequentially. The organic phase was separated, washed with saturated brine (2 × 50 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain compound 17 (2.64 g, 95.1%) as a pale yellow solid. MS (ESI, pos. ion) m / z: 302.4 [M+Na] + .
[0390] Step 2: Synthesis of compound 18
[0391] Compound 17 (2.50 g, 8.95 mmol) and sodium azide (1.16 g, 17.9 mmol) were added to DMF (40 mL) and stirred at 70°C for 21 h. The mixture was cooled to room temperature, and EA (300 mL) and water (200 mL) were added. The organic phase was separated, washed with saturated brine (2 × 200 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain an oil. After cooling, a white solid, Compound 18 (2.0 g, 98.76%), was obtained. MS (ESI, pos. ion) m / z: 227.1 [M+H] + .
[0392] Step 3: Synthesis of compound 19
[0393] 18 (0.53 g, 2.34 mmol) and triphenylphosphine (0.92 g, 3.51 mmol) were dissolved in tetrahydrofuran (11.5 mL) and water (0.23 mL) and stirred at room temperature for 10 h. After the reaction, the reaction solution was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to obtain a slightly yellow viscous compound 19 (0.44 g, 93.8%). MS (ESI, pos. ion) m / z: 201.3 [M+H] + .
[0394] Step 4: Synthesis of compound 21
[0395] Compound 10 (1.11 g, 2.48 mmol), HOBT (0.46 g, 3.38 mmol), and HBTU (1.28 g, 3.38 mmol) were dissolved in DMF (5 mL) and stirred at 25°C for 5 min. A solution of compound 19 (0.45 g, 2.25 mmol) in DMF (1 mL) was then slowly added dropwise, followed by DIPEA (2.61 mL, 15.75 mmol). The reaction mixture was allowed to react at room temperature for 18 h. After completion of the reaction, the mixture was diluted with DCM (200 mL) and washed sequentially with saturated sodium bicarbonate solution (20 mL), brine (5%, 100 mL x 2), and saturated brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (MeOH / DCM (v / v) = 1 / 5) to afford compound 21 (0.85 g, 60.08%) as a white solid. MS (ESI, pos.ion) m / z: 630.7 [M+H] + .
[0396] Step 5: Synthesis of compound 22
[0397] Compound 21 (3.4 g, 5.4 mmol) was dissolved in DCM (54 mL), and then TFA (4.01 mL, 54 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure to give a slightly yellow oil 22 (3.47 g, 102.3%). MS (ESI, pos. ion) m / z: 530.1 [M+H] + .
[0398] Step 6: Synthesis of compound 23
[0399] Compound 23 was prepared by the synthetic method of step 6 of reference example 1 as a white solid (1.6 g, 47%). MS (ESI, pos.ion) m / z: 2173.0588 [MH] - .
[0400] Step 7: Synthesis of compound 24
[0401] Compound 24 was prepared by the synthetic method of step 7 of Reference Example 1 as a white solid (1.53 g, 84.21%). MS (ESI, pos.ion) m / z: 1042.3 [M / 2+H] + .
[0402] Step 8: Synthesis of compound DAW40004-1
[0403] Compound DAW40004-1 was prepared by the synthetic method of step 8 of reference example 1 as a light yellow solid (0.40 g, 33.5%). MS (ESI, pos.ion) m / z: 2484.2 [M+H] + .
[0404] Step 9: Synthesis of compound DAW40004-2
[0405] Compound DAW40004-2 was prepared by the synthetic method of Reference Example 1, Step 9, as a white solid (0.4 g, 96.13%). MS (ESI, pos.ion) m / z: 1291.6 [M / 2+H] + .
[0406] Step 10: Synthesis of compound DAW40004-3
[0407] Compound DAW40004-3 was prepared by the synthetic method of Reference Example 1, Step 10, as a white solid DAW40004 (1.59 g) with a measured loading of 25.94 μmol / g.
[0408] Example 3: DAW40005-3
[0409] Step 1: Synthesis of compound 28
[0410] Compound 27 (1.52 g, 3.5 mmol) (prepared according to the synthetic method in Journal of Organic Chemistry (2020), 85 (10), 6593-6604), HOBT (0.71 g, 5.25 mmol) and HBTU (1.99 g, 5.25 mmol) were dissolved in DMF (10 mL), stirred at 25 ° C for 5 min, and then a DMF (2 mL) solution of compound 19 (0.7 g, 3.5 mmol) was slowly added dropwise, followed by the addition of DIPEA (2.9 mL, 17.5 mmol), and the reaction mixture was reacted at room temperature for 16 h. Water (30 mL) was added to dilute the mixture, followed by extraction with EA (50 mL × 4). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM to MeOH / DCM (V / V) = 1 / 10) to give compound 28 (1.24 g, 57.63%) as a white solid. MS (ESI, pos. ion) m / z: 616.6 [M+H] + .
[0411] Step 2: Synthesis of compound 29
[0412] Compound 28 (0.60 g, 0.97 mmol) was dissolved in DCM (8 mL), and then TFA (0.72 mL, 9.7 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure to give compound 29 (0.60 g, 97.95%) as a brown oil. MS (ESI, pos.ion) m / z: 516.6 [M+H] + .
[0413] Step 3: Synthesis of compound 30
[0414] Compound 6 (0.19 g, 0.30 mmol), compound 29 (0.66 g, 1.05 mmol), HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol), and DIPEA (0.50 mL, 3 mmol) were dissolved in DCM (20 mL) and stirred at room temperature for 16 h. The reaction was quenched by the addition of water (20 mL). The mixture was extracted with DCM (100 mL × 2) and washed sequentially with saturated sodium bicarbonate (40 mL) and saturated sodium chloride solution (40 mL). The mixture was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 10 / 1) to give compound 30 (0.275 g, 43.42%) as a white solid. MS (ESI, pos. ion) m / z: 1066.7 [M / 2+H] + .
[0415] Step 4: Synthesis of compound 31
[0416] Compound 31 was prepared by the synthetic method of step 7 of reference example 1 as a white solid (0.26 g, 98.72%). MS (ESI, pos.ion) m / z: 1022.5 [M / 2+H] + .
[0417] Step 5: Synthesis of compound DAW40005-1
[0418] Compound DAW40005-1 was prepared by the synthetic method of step 8 of reference example 1 as a light yellow solid (0.08 g, 25.8%). MS (ESI, negative ion) m / z: 2442.1 [MH] - .
[0419] Step 6: Synthesis of compound DAW40005-2
[0420] Compound DAW40005-2 was prepared by the synthetic method of step 9 of reference example 1 as a white solid (0.08 g, 96.07%). MS (ESI, pos.ion) m / z: 2542.2 [MH] - .
[0421] Step 7: Synthesis of compound DAW40005-3
[0422] Compound DAW40005-3 was prepared by the synthetic method of Reference Example 1, step 10, as a white solid (0.22 g) with a measured loading of 22.32 μmol / g.
[0423] Example 4: DAW40002-3
[0424] Step 1: Synthesis of compound 35
[0425] Compound 34 (2.50 g, 28.05 mmol) and triethylamine (7.8 mL, 56.1 mmol) were dissolved in DCM (120 mL), and benzyl chloroformate (9.57 g, 56.1 mmol) was added dropwise at 0°C. After the addition, the reaction mixture was warmed to room temperature and stirred for 20 h. Saturated ammonium chloride solution (50 mL) was added for dilution. The layers were separated, the aqueous phase was discarded, and the organic phase was concentrated. The resulting residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 30) to obtain Compound 35 (2.96 g, 47.2%) as a white solid.
[0426] MS (ESI, pos.ion) m / z: 224.2 [M+H] + ;
[0427] 1 H NMR(400MHz, CDCl3)δ7.37(d,J=4.2Hz,5H),5.11(s,2H),5.00(s,1H),4.19–4.14(m,1H),3.70–3.64(m, 2H), 3.24 (t, J=6.4Hz, 2H), 3.15 (q, J=4.6Hz, 1H), 1.90 (dq, J=14.2, 5.0, 4.3Hz, 2H), 1.77–1.71 (m, 1H).
[0428] Step 2: Synthesis of compound 37
[0429] Compound 36 (1.5 g, 4.56 mmol) and compound 35 (1.22 g, 5.47 mmol) were dissolved in 1,2-dichloroethane (30 mL), and 3A molecular sieves (2.0 g) were added. The mixture was stirred at room temperature for 10 min. TMSOTf (0.51 g, 2.28 mmol) was then added, and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured into saturated sodium bicarbonate solution (100 mL), extracted with DCM (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (PE / EA (v / v) = 2 / 1 to EA) to afford compound 37 (1.8 g, 71.51%) as a light brown oil. MS (ESI, pos. ion) m / z: 553.3 [M+H] + .
[0430] Step 3: Synthesis of compound 38
[0431] Compound 37 (0.57 g, 1.03 mmol) and palladium carbon (0.11 g, 0.1 mmol, 10%) were added to THF (10 mL), followed by the addition of TFA (0.12 g, 1.03 mmol). The mixture was then replaced with hydrogen three times and stirred at room temperature under a hydrogen atmosphere for 19 h. After the reaction was complete, the mixture was filtered through celite and the solvent was evaporated under reduced pressure to give compound 38 (0.55 g, 100.32%) as a light brown oil. MS (ESI, pos. ion) m / z: 419.3 [M+H] + .
[0432] Step 4: Synthesis of compound 40
[0433] Compound 39 (0.55 g, 2.55 mmol) and compound 38 (1.45 g, 2.8 mmol) were dissolved in DCM (30 mL), followed by the addition of HBTU (1.50 g, 3.95 mmol) and DIPEA (1.4 mL, 8.47 mmol). The reaction mixture was allowed to react at room temperature for 16 h. After completion of the reaction, water (20 mL) and DCM (100 mL) were added, followed by dilution. The organic phase was washed with saturated sodium bicarbonate solution (20 mL) and saturated brine (20 mL). The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (MeOH / EA (v / v) = 1 / 20) to afford compound 40 (0.60 g, 38%) as a white solid. MS (ESI, pos. ion) m / z: 616.6 [M+H] + .
[0434] Step 5: Synthesis of compound 41
[0435] Compound 40 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), TFA (0.87 mL, 11.7 mmol) was added, and the mixture was stirred at 25°C for 16 h. The solvent was concentrated to obtain compound 41 (0.74 g, 100%) as a brown oil. MS (ESI, pos.ion) m / z: 516.3 [M+H] + .
[0436] Step 6: Synthesis of compound 42
[0437] Compound 6 (0.30 g, 0.42 mmol, i.e., Compound 6 in Example 1, prepared by the synthetic method of Compound 6 in Example 1) and Compound 41 (0.71 g, 1.39 mmol) were dissolved in DCM (30 mL). HOBT (0.24 mL, 1.76 mmol), HBTU (0.67 g, 1.76 mmol), and DIPEA (0.7 mL, 4.2 mmol) were added, and the reaction mixture was stirred at 30°C for 3 h. The reaction was quenched by the addition of water (20 mL) and extracted with DCM (100 mL × 2). The organic phases were combined and washed sequentially with saturated sodium bicarbonate (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM to DCM / MeOH (V / V = 10 / 1)) to afford Compound 42 (0.15 g, 17%) as a white solid. MS(ESI,pos.ion)m / z:1066.2[M / 2+H] + .
[0438] Step 7 to Step 9: Synthesis of Compound 43, Compound DAW40002-1 and Compound DAW40002-2
[0439] Compound 43, compound DAW40002-1 and compound DAW40002-2 were prepared by the synthetic methods according to steps 7 to 9 of Example 1, respectively.
[0440] Compound DAW40002-1 was a white solid (0.083 g, 36.5%), HRMS (ESI, negative ion) m / z: 2442.1905 [MH] - ;
[0441] Compound DAW40002-2 was a white solid (0.08 g, 96.07%), HRMS (ESI, negative ion) m / z: 2542.1929 [MH] - .
[0442] Step 10: Synthesis of compound DAW40002-3
[0443] Compound DAW40002-3 was prepared by the synthetic method of step 10 of reference example 1 as a white solid (0.35 g) with a measured loading of 21.806 uM / g.
[0444] Example 5: Compound DAW40007-3
[0445] Step 1: Synthesis of compound 46
[0446] Compound 45 (0.46 g, 2.29 mmol, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and compound 38 (1.16 g, 2.18 mmol, i.e., compound 38 in Example 4, prepared by the synthetic method of compound 38 in Example 1) were dissolved in DCM (30 mL). HOBT (0.46 g, 3.44 mmol), HBTU (1.30 g, 3.44 mmol), and DIPEA (2.66 mL, 16.03 mmol) were added sequentially. The reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (50 mL × 2) were added sequentially. The organic phase was washed sequentially with saturated sodium bicarbonate solution (30 mL) and saturated brine (20 mL). The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (MeOH / EA (v / v) = 1 / 20) to obtain 46 (1.0 g, 72.7%) as a white solid.
[0447] MS (ESI, pos.ion) m / z: 602.3 [M+H] + ;
[0448] 1 H NMR (400MHz, CD3OD) δ5.39–5.33(m,1H),5.07(dd,J=11.2,3.4Hz,1H),4.58(d,J= 8.4Hz,1H),4.21–4.09(m,3H),4.04(t,J=6.7Hz,1H),3.89(dt,J=10.4,5.1Hz,1H ),3.60–3.50(m,1H),3.30–3.13(m,2H),2.16(s,3H),2.04(s,3H),1.97(s,3H),1 .94(s,3H),1.67–1.56(m,4H),1.48(s,9H),1.41–1.37(m,2H),1.02–0.98(m,2H).
[0449] Step 2: Synthesis of compound 47
[0450] Compound 46 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), and then TFA (0.87 mL, 11.7 mmol) was added. The reaction mixture was stirred at 25°C for 16 h, and the solvent was concentrated to give compound 47 (0.74 g, 103.1%) as a brown oil.
[0451] MS (ESI, pos.ion) m / z: 502.2 [M+H] + ;
[0452] 1H NMR (400MHz, CD3OD) δ5.36 (d, J=3.3Hz, 1H), 5.08 (dd, J=11.3, 3.3Hz, 1H), 4.58 (d, J=8.4Hz, 1H),4.16–4.10(m,3H),4.08–4.02(m,1H),3.92–3.85(m,1H),3.58–3.50(m,1H),3.26–3.20(m,2H),2.16(s,3 H), 2.04 (d, J = 5.2Hz, 6H), 1.98 (s, 3H), 1.97 (s, 3H), 1.61–1.56 (m, 4H), 1.54–1.52 (m, 2H), 1.42–1.38 (m, 2H).
[0453] Step 3: Synthesis of compound 48
[0454] Compound 6 (0.19 g, 0.3 mmol, i.e., Compound 6 in Example 1, which was prepared according to the synthesis method of Compound 6 in Example 1) and Compound 47 (0.5 g, 0.99 mmol) were dissolved in DCM (30 mL). HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol), and DIPEA (0.5 mL, 3.0 mmol) were then added sequentially. The reaction mixture was stirred at 30°C for 3 h. After completion of the reaction, water (20 mL) was added to quench the reaction, followed by extraction with DCM (100 mL × 2). The organic phases were combined, washed sequentially with saturated sodium bicarbonate solution (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM to DCM / MeOH (v / v) = 10 / 1) to afford Compound 48 (0.23 g, 37%) as a white solid.
[0455] MS(ESI,pos.ion)m / z:1046.3[M / 2+H] + ;
[0456] 1H NMR (400MHz, CD3OD) δ7.78(t,J=5.8Hz,2H),7.38–7.36(m,3H),5.36(d,J=3.4Hz,3H),5.13(s,2H),5.08(dd,J=11.2, 3.4Hz,3H),4.58(d,J=8.4Hz,3H),4.21–4.08(m,9H),4.04(t,J=6.7Hz,3H),3.93–3.82(m,3H),3.73–3.66(m,12H),3. 60–3.52(m,3H),3.29–3.18(m,6H),2.52(t,J=6.0Hz,6H),2.38(t,J=7.4Hz,2H),2.20(t,J=7.7Hz,2H),2.16(s,9H), 2.04(s,9H),1.97(s,9H),1.95(s,9H),1.62–1.56(m,12H),1.50–1.42(m,6H),1.35–1.27(m,16H),1.04–0.97(m,6H).
[0457] Step 4: Synthesis of compound 49
[0458] Compound 48 (0.20 g, 0.094 mmol) was dissolved in methanol (10 mL), and then Pd / C (10 mg, 10%) was added. The atmosphere was replaced with hydrogen three times, and the reaction mixture was stirred at room temperature for 11 h under a hydrogen atmosphere. After the reaction was complete, the reaction mixture was filtered through celite, and the filtrate was evaporated to dryness under reduced pressure to obtain compound 49 (0.19 g, 100%) as a white solid.
[0459] MS(ESI,pos.ion)m / z:1001.1,[M / 2+H] + .
[0460] Step 5: Synthesis of compound DAW40007-1
[0461] Compound 49 (0.28 g, 0.14 mmol) was dissolved in DCM (20 mL), and HOBT (0.038 g, 0.28 mmol), HBTU (0.080 g, 0.21 mmol), DIPEA (0.054 g, 0.42 mmol) and compound 13 (0.068 g, 0.16 mmol) were added in sequence. The reaction mixture was stirred at room temperature for 13 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with DCM (20 mL). The organic phase was washed with saturated sodium bicarbonate solution (10 mL) and the mixture was evaporated under reduced pressure. The solvent was evaporated to dryness, and the resulting residue was dissolved in acetonitrile (10 mL) and separated by reverse preparative column chromatography (acetonitrile / water solution (v / v) = 43% to 60%, 50 min). Salt was added to the product-containing solution after preparative separation to saturate the solution. The organic phase was separated, and the aqueous phase was extracted with acetonitrile (100 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was added to acetonitrile (30 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound DAW40007-1 (0.08 g, 24%) as a pale yellow solid.
[0462] MS(ESI,neg.ion)m / z:2400.18[MH] - ;
[0463] 1 H NMR(400MHz, DMSO-d6)δ8.31(s,3H),7.81(d,J=9.2Hz,3H),7.57(t,J=6.0Hz,3H),7.35–7.26(m,4H),7 .20(td,J=8.9,3.0Hz,5H),6.95(s,1H),6.88(ddd,J=8.8,5.8,2.2Hz,4H),5.22(d,J=3.4Hz,3H),4.97 (dd,J=11.2,3.5Hz,4H),4.49(d,J=8.5Hz,3H),4.40(d,J=4.8Hz,1H),4.15(s,1H),4.07–4.00(m,9H), 3.88(dt,J=11.2,8.8Hz,3H),3.74(s,9H),3.59–3.48(m,12H),3.17(dd,J=8.8,5.0Hz,1H),3.10–2.95 (m,8H),2.35(t,J=6.3Hz,6H),2.10(s,9H),2.08(s,3H),2.04(d,J=4.7Hz,2H),2.00(s,9H),1.89(s,9H),
[0464] 1.78(s,9H),1.40(d,J=12.2Hz,17H),1.31–1.16(m,18H),0.79(q,J=3.2Hz,6H).
[0465] Step 6: Synthesis of compound DAW40007-2
[0466] Compound DAW40007-1 (0.080 g, 0.033 mmol) was dissolved in DCM (10 mL), and DIPEA (0.029 mL, 0.17 mmol), succinic anhydride (0.008 g, 0.083 mmol) and DMAP (0.014 g, 0.12 mmol) were added. The mixture was stirred at 40°C for 5 h, and succinic anhydride (10 mg) was added. After the reaction was continued for 16 h, DCM (10 mL), succinic anhydride (10 mg) and DIPEA (0.05 mL) were added. The mixture was stirred for another 9 h, and then succinic anhydride (10 mg) was added. After the reaction was continued for another 10 h, DCM (20 mL) was added to dilute the mixture, and the mixture was washed with saturated sodium bicarbonate solution (10 mL). The aqueous phase was discarded, and the organic phase was dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to obtain compound DAW40007-2 (0.08 g, 96.07%) as a white solid. MS(ESI,neg.ion)m / z:2500.12[MH] - .
[0467] 1H NMR (400MHz, DMSO-d6) δ8.45(d,J=6.6Hz,2H),7.85(d,J=9.2Hz,3H),7.62(d,J=5.2Hz,3H),7.37–7.26(m,4H),7.25–7.17(m,5H),7.01(s,1H) ,6.92–6.83(m,4H),5.22(d,J=3.4Hz,3H),4.98(dd,J=11.2,3.4Hz,3H) ,4.50(d,J=8.5Hz,3H),4.24–4.12(m,2H),4.03(s,9H),3.93–3.85(m,4 H),3.74(s,6H),3.72–3.64(m,4H),3.63–3.48(m,13H),3.47–3.38(m,4 H),3.28–3.19(m,1H),3.10–3.01(m,6H),2.35(t,J=6.6Hz,8H),2.25–2 .17(m,2H),2.11(s,9H),2.07–2.03(m,2H),2.00(s,9H),1.89(s,9H),1 .78(s,9H),1.48–1.36(m,16H),1.27–1.15(m,20H),0.82–0.75(m,6H).
[0468] Step 7: Synthesis of compound DAW40007-3
[0469] Compound DAW40007-2 (0.08 g, 0.032 mmol), HBTU (0.015 g, 0.04 mmol), and DIPEA (0.011 mL, 0.064 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. The mixture was then transferred to a solid-phase synthesizer containing 0.35 g of H2N-CPG (purchased from Hebei Dinaxingke) and shaken for 22.5 h. The mixture was filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL), and dried. The resulting filter cake was diluted in 25% Ac2O / Py solution (5 mL) and stirred for 3 h. The mixture was filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in sequence, and dried under reduced pressure to give a white solid DAW40007-3 (0.357 g) with a measured loading of 14.95 μmol / g.
[0470] Synthesis of compound L96
[0471] Compound L96 was prepared according to the method described in patent application WO2014025805A1.
[0472] The structure of the L96 conjugated group is:
[0473] In addition, the compound of the present invention is linked to the siRNA molecule according to methods known in the art, and the protection is removed to obtain a siRNA conjugate containing the conjugated group of the present application, such as DAW40007-3 and siRNA are linked and the protecting group is removed to form a siRNA conjugate containing the DAW40007-4 conjugated group (i.e., siRNA drug).
[0474] Example 6: Synthesis of siRNA conjugates
[0475] The synthesis method of the antisense strand us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7) is as follows:
[0476] The synthesis specification was completed according to the theoretical yield of 1umol. Weigh 1umol of solid phase support CPG (purchased from Hebei Dinaxingke), 2'-methoxy nucleoside monomer and 2'-fluoro nucleoside monomer (purchased from Wuhu Huaren Technology) and AgN monomer (purchased from Beijing Coupling Technology Co., Ltd.) and provide them in 0.1M anhydrous acetonitrile solution. For oligonucleotides with phosphate backbone thiolation modification, 0.1M DDTT solution was used as the thiolation reagent. 5-Ethylthio-1H-tetrazole acetonitrile solution (0.25M) was used as an activator (purchased from Suzhou Kelema), 0.02M iodine pyridine / water solution was used as an oxidant, and 3% trichloroacetic acid in dichloromethane was used as a deprotection reagent, which were placed in the designated reagent position corresponding to the KA-H8 model DNA / RNA automatic synthesizer. Set the synthesis program and enter the specified oligonucleotide base sequence. After checking that everything is correct, start the cyclic oligonucleotide synthesis. The coupling time for each step is 6 minutes and the sulfurization time is 6 minutes. After automatic circulation, the oligonucleotide containing solid support CPG is obtained.
[0477] The CPG-containing nucleotides obtained above were dried with dry argon and then transferred to a 2 mL EP tube. 28% aqueous ammonia solution (1.8 mL) was added and heated at 55°C for 5 to 18 hours. The mixture was filtered, the filter cake washed with water (0.5 mL), and the filtrates were combined and concentrated under reduced pressure to obtain a white or yellow colloidal solid. After reverse-phase preparative purification, the preparative solution was concentrated and passed through a gel column to remove excess salts to obtain the oligonucleotides. The concentration of the resulting oligonucleotides was determined using a micro-UV spectrophotometer (SPECTRO stat Nano). Mass spectrometry analysis was performed on an Agilent 6530 LC-MS Q-Tof system. After primary scanning, the nucleic acid molecular weight was calculated after deconvolution. The measured values were consistent with the theoretical values, indicating that the target antisense strand was synthesized.
[0478] Synthesis of the sense strand of siRNA conjugates:
[0479] The present invention prepared the sense strand of the siRNA conjugate by replacing the conventional solid-phase support CPG with the GalNAc solid-phase support CPG prepared in this invention, and following the method for synthesizing the antisense strand. The measured molecular weights of the sense strands of the siRNA conjugates were consistent with the theoretical values, indicating that the target siRNA sense strand was synthesized. The HPLC purity and measured molecular weights of the sense strands of some siRNA conjugates are shown in Table 1 below:
[0480] Table 1: HPLC purity and measured molecular weight of the sense strand of siRNA conjugates
[0481] Annealing step: The sense strand of the synthesized siRNA conjugate was mixed with the antisense strand in equimolar amounts, heated to 95°C, maintained at this temperature for 10 minutes, and then slowly cooled to room temperature. The target siRNA conjugate was then lyophilized to obtain the target siRNA conjugate, whose number and sequence are shown in Table 2 below.
[0482] Table 2: siRNA conjugate numbers and their corresponding sense strands (containing conjugate groups) and reaction strands
[0483] The base letters are lowercase 2'-OMe modified, f is 2'-F modified, s is phosphate backbone thio modification, Agn is adenosine-diol nucleic acid (GNA) modified, Tgn represents a thymine-diol nucleotide residue, DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are the conjugate groups described in the present invention, each of which is independently conjugated to the 3' end of the sense chain through a phosphate group.
[0484] Example 7: Hepatitis B virus transgenic mouse experiment
[0485] Experimental methods
[0486] Experimental animals: HBV-Tg transgenic mice, C57B / 6N-Tg (1.28HBV) / Vst, SPF-grade male, 6-8 weeks old, 16-20 g, purchased from Beijing Weitongda Biotechnology Co., Ltd., animal production certificate number: SCXK (Beijing) 2019-0002. The animals were raised by Beijing Weitongda Biotechnology Co., Ltd. and kept in individual cages.
[0487] Animal grouping: According to the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), the animals were stratified and randomly divided into groups, with 5 animals in each group.
[0488] Test Article Preparation and Administration: Calculate the required dosage of drug powder based on the purity of each test article. Add the appropriate saline solution at a dosing concentration of 0.6 mg / mL and vortex to mix until a colorless, transparent liquid is obtained. The day of the first dose is designated Day 0. All groups of animals received a single subcutaneous dose of 5 mL / kg on Day 0. If blood sampling is required on the day of dosing, administer the drug after blood collection.
[0489] Main outcome measures: Patients were weighed and blood was collected once on the 3rd, 7th, 14th, 21st, 28th, and 35th day, and serum was separated for determination of HBsAg and HBeAg levels.
[0490] Serum HBsAg and HBeAg Levels: After blood collection, serum was separated and diluted with PBS solution before testing. 10 μL of serum was collected from each sample and diluted to 500 μL (50-fold dilution) with PBS solution. Serum HBsAg and HBeAg levels were measured using a Hepatitis B e Antigen Assay Kit (Mike Biotech) and a Hepatitis B Surface Antigen Assay Kit (Mike Biotech), respectively.
[0491] Results of Hepatitis B Virus Transgenic Mouse Experiments
[0492] The experimental results show that the siRNA conjugates of the present invention can significantly reduce HBsAg in the Tg / HBV mouse model experiment. Moreover, compared with the vector L96 used by the four currently marketed Galnac-siRNAs, while ensuring the same sequence, the siRNA conjugates of the present invention are superior to the siRNA conjugate DAW30025 using L96 in reducing HBsAg, such as the siRNA conjugates DAW30221, DAW30222 and DAW3022 of the present invention. 3 (the carriers used, also known as conjugation groups, correspond to DAW40002-4, DAW40005-4, and DAW40007-4, respectively) were significantly superior to the siRNA conjugate DAW30025 using L96 in reducing HBsAg. The siRNA conjugates of the present invention exhibited a more sustained HBsAg-lowering effect (see Figure 1 for the HBsAg-inhibiting effects of the conjugates DAW30221, DAW30222, DAW30223, and DAW30025 of the present invention). Furthermore, the siRNA conjugates of the present invention also exhibited a significant inhibitory effect on HBeAg in a Tg / HBV mouse model.
[0493] Example 8: In vivo knockdown activity test of AGT siRNA conjugate in mice
[0494] Experimental methods:
[0495] To evaluate the in vivo activity of the siRNA conjugates containing the present invention coupled to the GalNAc carrier against AGT, an AGT humanized mouse model (6-9 mice per group) was used. Baseline serum was collected from each group of mice 3 days before administration. A single dose of 1 mg / kg or 3 mg / kg of the present GalNAc-siRNA or vehicle was administered subcutaneously at the back of the neck on D0. Blood samples were collected on D4 / 7 / 14 / 21 / 28 / 35 / 49, and human AGT protein concentration was measured by ELISA (ab287170). The knockdown percentage was calculated by comparing the human AGT protein levels in the siRNA group and the vehicle group. The knockdown effect of DAW30255 on AGT is shown in Figure 2. The experimental results showed that the siRNA conjugates of the present invention can significantly reduce the expression of AGT. Therefore, DAW30255 of the present invention has good application prospects for the treatment of hypertension.
[0496] The above mouse experiments show that the GalNAc vector of the present invention has a good delivery effect on AGT and HBV target siRNA drugs. According to common knowledge in the field, a specific embodiment of the present invention is that the vector delivers anti-hepatitis B drugs for the treatment of hepatitis B, or AGT drugs for the treatment of hypertension through liver-targeted delivery, which has a good delivery effect. Therefore, the vector of the present invention can also be used for the delivery of other liver-targeted indications.
[0497] Although the present invention has been described in detail above using general explanations, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.
Claims
1. A compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I), in, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms; Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)- or MC(=O)(CH2) j C(=O)-; M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG; Each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; R is a structure represented by the following formula (a) or formula (b): Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H or a hydroxyl protecting group; each Y1, Y2, Y3, Y4, Y5 is independently H or an amino protecting group; Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; Each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkane Base, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; Each R 1 are independently H, deuterium or C 1-6 alkyl; wherein each j is independently 1, 2, 3, 4 or 5; Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
2. The compound according to claim 1, wherein Each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
3. The compound according to claim 1 or 2, wherein Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
4. The compound according to any one of claims 1 to 3, wherein Each of B1, B2, B3, B4 and B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
5. The compound according to any one of claims 1 to 4, wherein Z and Y are each independently H, deuterium, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkyl methyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkyl methyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkyl methyl, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkyl methyl, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
6. The compound according to any one of claims 1 to 5, wherein Each X1, X2, X3, X4, X5, X6, X7, X8, X9, 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-; Each of Y1, Y2, Y3, Y4 and Y5 is independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-; Among them, each R 2 and R 3 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl; or Each R 2 and R 3 Independently for C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl; or Each R 2 and R 3 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl; Each R 1 are independently H, deuterium or C 1-4 alkyl; Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
7. The compound according to any one of claims 1 to 6, wherein R is a structure represented by the following formula (a-1) or formula (b-1): Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 The definitions of Y1, Y2, Y3, Y4, Y5, A1, A2, A3, A4, A5, B1, B2, B3, B4, B5, C1, C2, C3, C4 and C5 have the meanings as described in any one of claims 1-6.
8. A compound according to any one of claims 1 to 7, having a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II), in, The definitions of Z, Y, L1, L2, L3 and R have the meanings as described in any one of claims 1-6.
9. A compound according to any one of claims 1 to 8, having a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III), in, Each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ; each of F1, F2 and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl; Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4; Among them, each R 1 , X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y3, Y4, Y5, Z and Y have the meanings as described in any one of claims 1-6.
10. The compound according to any one of claims 1 to 9, which has one of the compounds shown below, or a stereoisomer, tautomer or acceptable salt thereof, M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, and further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG.
11. A conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia), in, R x It is a structure of formula (c) or formula (d): Each ring A, A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4, Y5, L1, L2 and L3 have the meanings as described in any one of claims 1-6.
12. The conjugated group according to claim 11, wherein R x It is a structure shown in the following formula (c-1) or formula (d-1): Among them, A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4 and Y5 have the meanings as described in any one of claims 1-6.
13. The conjugated group according to claim 11 or 12, which has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a), Each R x The definitions of L1, L2 and L3 have the meanings as described in any one of claims 1-6.
14. The conjugated group according to any one of claims 11 to 13, which has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a), in, Each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ; Each of F1, F2 and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4; Among them, each R 1 , Y3, Y4 and Y5 have the meanings as defined in any one of claims 1-6.
15. The conjugated group according to any one of claims 11 to 14, which has one of the structures shown below, or a stereoisomer, tautomer or acceptable salt thereof, 16 . A nucleic acid conjugate, comprising the conjugated group according to any one of claims 11 to 15 and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid. The nucleic acid conjugate according to claim 16 , wherein the nucleic acid is linked to the conjugated group via a phosphate group, a phosphorothioate group or a phosphate group. The nucleic acid conjugate according to claim 16 or 17, wherein the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
19. The nucleic acid conjugate according to any one of claims 16 to 18, wherein the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, more preferably to the 3' end of the sense strand of the siRNA.
20. An siRNA conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255, DAW30223: DAW30223: Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40002-4 (SEQ ID NO: 2) Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7) DAW30062: Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40003-4 (SEQ ID NO: 3) Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7) DAW30219: Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40004-4 (SEQ ID NO: 4) Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7) DAW30221: Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40005-4 (SEQ ID NO: 5) Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7) DAW30222: Sense strand (5’-3’): gs-us-g-u-Gf-c-Af-Cf-Uf-u-c-g-c-u-u-c-a-c-a-DAW40007-4 (SEQ ID NO: 6) Antisense strand (5’-3’): us-Gfs-u-g-a-Agn-g-Cf-Gf-a-a-g-u-Gf-c-Af-c-a-cs-us-u (SEQ ID NO: 7) DAW30255: Sense strand (5’-3’): gs-us-c-a-u-c-Cf-a-Cf-Af-Af-u-g-a-g-a-g-u-a-c-a-DAW40007-4 (SEQ ID NO: 8) Antisense strand (5’-3’): us-Gfs-u-a-c-(Tgn)-c-u-c-a-u-u-g-Uf-g-Gf-a-u-g-a-cs-gs-a (SEQ ID NO: 9) in, The conjugate groups DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are each conjugated to the 3' end of the siRNA sense strand via a phosphate group, and the structures thereof are shown below:
21. A pharmaceutical composition comprising the siRNA conjugate according to claim 20 and a pharmaceutically acceptable carrier.
22. Use of the compound of any one of claims 1 to 10, the conjugated group of any one of claims 11 to 15, or the nucleic acid conjugate of claims 16 to 19 in the preparation of a medicament for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in hepatocytes.
23. The use according to claim 22, wherein the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
24. Use of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof, in the preparation of a medicament for treating and / or preventing hepatitis B disease, or use of DAW30255 or a combination thereof in the preparation of a medicament for treating and / or preventing hypertension.
25. The compound of any one of claims 1-10 or the conjugated group of any one of claims 11-15 is used for the delivery of drugs for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes, and the nucleic acid conjugate of claims 16-19 is used for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
26. The compound, conjugate or nucleic acid conjugate according to claim 25, wherein the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
27. siRNA drugs DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof for treating and / or preventing hepatitis B disease, or DAW30255 or a combination thereof for treating and / or preventing hypertension.
28. A method for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a hepatocyte, the method comprising using the compound of any one of claims 1 to 10 or the conjugated group of any one of claims 11 to 15 as a drug delivery system, or the method comprising administering the nucleic acid conjugate of claims 16 to 19.
29. The method of claim 28, wherein the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
30. A method for preventing, managing, treating or alleviating hepatitis B disease or hypertension, comprising administering to a patient an effective therapeutic amount of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof; or administering to a patient an effective therapeutic amount of DAW30255 or a combination thereof.
Citation Information
Patent Citations
Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009073809A2
Carbohydrate conjugated RNA agents and process for their preparation
WO2014025805A1
Bivalent targeted conjugates
WO2020093053A1
Carbohydrate conjugated RNA agents and process for their preparation
CN104717982A
Conjugates and preparation and use thereof
CN110959011A
Cited By
Conjugate and use thereof
WO2025223424A1
